Search for: "Bristol Myers Squibb Manufacturing Company"
Results 141 - 160
of 161
Sort by Relevance
|
Sort by Date
20 Mar 2009, 2:05 am
Squibb & Sons, Inc. v. [read post]
3 Mar 2009, 5:55 am
After plaintiff reported the loss, defendant Erie Insurance Company began an investigation into the claim. [read post]
27 Feb 2009, 7:00 am
(Techdirt) How companies can cash in on innovations and patents (IP Frontline) International Property Rights Index 2009 - New report identifies world’s most IP-friendly country, but trade marks are ignored (IAM) What do clients want? [read post]
18 Jan 2009, 4:48 pm
Dasatinib is an anti-cancer drug belonging to the class of tyrosine kinase inhibitors first approved in the United States on June 28, 2006 and marketed by Bristol-Myer Squibb (BMS) under the brand name Sprycel. [read post]
15 Jan 2009, 3:35 am
Just to recap then, the High Court of Delhi recently granted an ex parte restraining order in favour of Bristol Myers Squibb restraining the defendants, Hetero Drugs (an Indian generic firm) from manufacturing, selling, distributing, advertising, exporting, offering for sale or in any manner dealing directly or indirectly in any product infringing the plaintiffs product patent covering Dasatinib, a drug used in the treatment of Chronic Myloeid Leukemia. [read post]
31 Dec 2008, 6:51 pm
Recent news reports have allowed us to add thirteen biotech/pharma companies and a trade group to the list: • The Pharmaceutical Research and Manufacturers of America (PhRMA), which has more than 30 members including Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Novartis Corp., Pfizer Inc., and Sanofi-Aventis SA, spent more than $5.4 million on third quarter… [read post]
15 Oct 2008, 3:02 pm
Much of the lobbying efforts were aimed at Sheldon Bradshaw, who had succeeded Daniel Troy as FDA chief counsel in April 2005.AAJ obtained emails that list attendees of a meeting between Bradshaw and the Pharmaceutical Research and Manufacturers of America (PhRMA) revealing the FDA chief counsel met with legal representatives from Pfizer, Wyeth, Eli Lilly, Berlex, Organon, Abbott Laboratories, Takeda, Sanofi-Aventis, Serono, AstraZeneca, Cephalon, Millenium, Eisai, Amgen, Astellas,… [read post]
29 Sep 2008, 8:14 pm
UAEM’s Argument The general proposition that drug companies should make medicines available to low income countries at the lowest possible cost is easy to support on a humanitarian level, but the proposition may appear less realistic on a practical level: pharmaceutical research and development are costly, as is the manufacture of drugs. [read post]
19 Sep 2008, 6:00 pm
Here is IP Think Tank’s weekly selection of top intellectual property news breaking in the blogosphere and internet. [read post]
23 Aug 2008, 1:23 am
: (Part 1 - SPICY IP), (Part 2 - SPICY IP) Global – Copyright International Federation of the Phonographic Industry (IFPI): ‘Three strikes’ effort hit worldwide home run: (Ars Technica), How to attribute a Creative Commons licensed work: (Molly Kleinman), Chrysalis disappoints, as new artists fail to incubate: (IP finance), DRM for streaming music dies a quiet death: (Electronic Frontier Foundation), (Techdirt) Events 26 August:… [read post]
16 Aug 2008, 2:43 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Belgium - eBay wins ruling against L’Oreal in dispute over liability for counterfeit goods sold in online auctions: (Managing Intellectual Property), (Counterfeit Chic), (IPKat), (Class 46), (Techdirt), (Ars Technica) US CAFC holds that copying free software without complying with license is copyright infringement: Robert Jacobsen v… [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at… [read post]
2 May 2008, 7:00 am
: Lupin v Abbott Labs: (FDA Law Blog), Plavix (Clopidogrel) – US: Apotex sues FDA to recover 180-day exclusivity on generic Plavix: (Orange Book Blog), Plavix (Clopidogrel) – US: Former Bristol-Myers Squibb executive charged over lying about Plavix deal struck with rival Apotex: (Managing Intellectual Property), Risperdal (Resperidone) – US: Apotex files motion to intervene in relisting of Risperdal patent case; Teva quickly files… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
27 Apr 2008, 9:57 pm
In March 2002, Sanofi-Synthelabo and Bristol-Myers Squibb sued Apotex for infringing the Orange Book-listed patent, U.S. [read post]
28 Mar 2008, 7:25 am
Proponents have withdrawn resolutions at Abbott Laboratories, Aetna, Bristol-Myers Squibb, Eli Lilly, General Electric, IBM, Johnson & Johnson, McDonald's, Medco, WellPoint, ExxonMobil, Merck, Target, and Waste Management after many of the companies agreed to post statements on health care reform on their Web sites. [read post]
20 Nov 2007, 7:18 am
Maxipime is manufactured by Bristol-Myers Squibb Co. [read post]
20 Jul 2007, 7:39 pm
This week, shortly before trial, pharmaceutical manufacturer Bristol-Myers Squibb Co. reportedly agreed to pay $13 million to resolve allegations that it overcharged for its Taxol cancer medicine and other drugs. [read post]
8 Jun 2007, 12:49 pm
The FTC warned Bristol-Myers that it would not approve a settlement of the Plavix litigation if the company agreed not to launch its own generic version of Plavix that would compete against Apotex for generic sales. [read post]
3 Apr 2007, 6:20 am
(noting that "Switzerland's Serono and Germany's Schering, Altana and Schwarz were all sold in 2006" and that "Britain's Astra Zeneca and America's Wyeth and Bristol-Myers Squibb" may be the next targets for larger, acquiring firms) [read post]
